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ABSTRACT:
The Global Cancer Genomics Consortium (GCGC) colleagues continue to function 
together as an interactive multidisciplinary team of cancer biologists and oncologists 
with interests in genomics and building a bidirectional bridge between cancer clinics 
and laboratories while taking advantage of shared resources among its member 
scientists. The GCGC includes member scientists from six institutions in Lisbon, 
United Kingdom, Japan, India and United States, and was formed in December 2010 
for a period of five years.  Driven by valuable lessons learned from the previous 
symposiums, the fourth GCGC Symposium focused on a cross section of genomic 
and epigenetic cancer medicine and it’s for this reason we chose the conference 
theme - New Era of Molecular Medicine and Epigenetic Cancer Medicine: Cross 
Section of Genomics and Epigenetics. This year’s symposium was co-organized by 
the Organization for Oncology and Translational Research (OOTR) at the Shiran Hall, 
Kyoto University, Kyoto, Japan, from November 14 and 15, 2014.  The symposium 
attracted around 80 participants from 14 countries, and counted with 23 invited 
platform speakers. Scientific sessions included eight platform sessions and one poster 
session, and three plenary lectures. The symposium focused on cancer stem cells 
and self-renewal, cancer transcriptome, tumor heterogeneity, tumor biology, breast 
cancer genomics, targeted therapeutics and personalized medicine. The issues of 
cancer stem cells and tumor heterogeneity were echoed in most of the scientific 
presentations. The meeting concluded with an oral presentation by the best poster 
awardee and closing remarks by meeting co-chairs.
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INTRODUCTION 
The Global Cancer Genomics Consortium 
(GCGC) colleagues continue to function together as an 
interactive multidisciplinary team of cancer biologists 
and oncologists with interests in cancer genomics and 
building a bidirectional bridge between cancer clinics and 
laboratories while taking advantage of shared resources 
among its member scientists. The GCGC includes 
member scientists from six institutions in Lisbon, United 
Kingdom, Japan, India and United States, and was formed 
in December 2010 for a period of five years.  Since the 
last successful Symposium in Lisbon, Portugal in 2013, 
the GCGC colleagues continue to function together 
as an interactive multidisciplinary team of cancer 
biologists and oncologists with interests in genomics and 
building a bidirectional bridge between cancer clinics 
and laboratories while taking an advantage of shared 
resources among its founding members. This collaborative 
network continues to enable cancer students and scholars 
in academics and research and helped to nurture a cross-
disciplinary collaborative approach among consortium 
members and meeting participants over the years. 
Motivated by valuable lessons learned from the 
previous symposiums, the fourth GCGC Symposium 
focused on a cross section of genomic and epigenetic 
cancer medicine. And it’s for this reason we chose the 
conference theme - New Era of Molecular Medicine and 
Epigenetic Cancer Medicine: Cross Section of Genomics 
and Epigenetics. This year’s symposium was co-organized 
by the Organization for Oncology and Translational 
Research (OOTR) at the Shiran Hall, Kyoto University, 
Kyoto, Japan, from November 14 and 15, 2014.  The 
symposium attracted around 80 participants from 14 
countries, and counted with 23 invited platform speakers 
and a rich poster session. 
Similar to previous years, the mission of the 
symposium was to provide practical knowledge on 
structural and cancer genomics approaches, to meet and 
share experiences of the like-minded cancer experts 
and leaders, to provide an exclusive platform for 
focused cancer genomics endeavors, and to evaluate the 
latest research developments in cancer genomics and 
epigenetics.
Focus on the Molecular Medicine and Epigenetic 
Cancer Medicine
The fourth GCGC meeting was at the interface of 
molecular cancer medicine, epigenetics and tumor biology 
with a particular focus on biologic questions within 
recognizable clinical framework with a forward looking 
approach. The event was opened by Dr. Masakazu Toi 
with a brief history of GCGC. Dr. Toi introduced the chief 
guest Prof. Nagahiro Minato, Executive Vice-President 
for Research, Planning, and Hospital Administration 
at the Kyoto University. Prof. Minato inaugurated the 
meeting by highlighting the contribution of genome 
research in cancer biology and treatment and the role 
played by the Kyoto University in the previous consortium 
meetings.  He stressed the need to developing efficient 
collaborative programs to understand the molecular and 
genomic details of human cancer and to develop targeted 
cancer therapeutic. Scientific sessions included eight 
platform sessions and one poster session, and included 
three plenary lectures. The symposium focused on the 
following scientific themes: 1) cancer stem cells and self-
renewal; 2) cancer transcriptome; 3) tumor heterogeneity; 
4) tumor biology; 5) breast cancer genomics; 6) targeted 
therapeutics; and 7) personalized medicine. The issues 
of cancer stem cells and tumor heterogeneity are echoed 
in most of the scientific presentations. The meeting 
concluded with an oral presentation by the best poster 
awardee and closing remarks by meeting co-chairs - Dr. 
Masakazu Toi and Dr. Rakesh Kumar.
Cancer Stem Cells and Self-renewal 
The theme was introduced by the opening 
conference lecture by Dr. Akihiko Yokoyama from the 
Laboratory of Malignancy Control Research, Kyoto 
University School of Medicine. Dr. Yokoyama presented 
new molecular insights by which Mixed-lineage 
leukemia fusion (MLL) oncogenes aberrantly regulate 
the expression of hematopoietic stem genes, leading to 
leukemia [1, 2]. Dr. Yokoyama provided experimental 
evidence to suggest that MLL fusion proteins recognize 
its target genes through specific bindings of the PWWP 
domain of LEDGF and the CXXC domain of MLL that 
specifically bind to H3K36me2/3 and non-methylated 
CpGs, respectively. Because H3K36me2/3 marks are 
generally linked to gene activation, this suggested that 
previously transcribed genes with non-methylated CpGs 
in its promoters are likely to be stimulated by MLL fusion 
proteins. Dr. Yokoyama suggested that in general, MLL 
fusion oncogenes function as a facilitator of self-renewal 
simply by continuously activating previously-active 
hematopoietic stem cell program genes to transform 
hematopoietic progenitors into cancer cells. 
Dr. Hiroshi Seno from the Department of 
Gastroenterology and Hepatology, Kyoto University 
Graduate School of Medicine highlighted the role of tumor 
stem cells in digestive tumors and presented data outlining 
the benefits of using lineage tracing approach in murine 
models in identifying tumor stem cells (TSCs) from 
resembling normal stem cells (NSCs) in the background 
of self-renewal and continuous supply of progeny tumor 
cells. Specifically, he utilized Dclk1creERT2/+ knock-in 
mice to understand the role of doublecortin-like kinase 
1 (Dclk1) in the intestinal tumors. Dr. Seno’s group 
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found that Dclk1 does not mark intestinal NSCs and that 
targeting Dclk1-marked TSCs marked could be used an 
antitumor therapy without any significant damages to the 
normal intestines in murine models. Dr. Seno suggested 
that Dclk1 might be a unique marker to discriminate tumor 
stem cells from normal stem cells in the mouse intestine.
Dr. Nobu Oshima from the Department of 
Reprogramming Science, Center for iPS Cell Research 
and Application at Kyoto University shared exciting data 
showing the ability of OCT3/4, SOX2 and KLF4 to induce 
cancer stem cell with self-renewing characteristics in 
colon cancer cells. He also presented a new methodology 
to collect the induced CSCs based on the dye-efflux 
activity enhancement. Dr. Oshima judged the functionality 
of induced CSC by its ability to differentiate in vivo and 
form tumors which remarkably mimicked actual human 
colon cancer tissues in terms of their pathological findings 
- intratumor heterogeneity and glandular-like structure. Dr. 
Oshima hopes that these methods will contribute towards 
the development of better therapeutic approaches targeting 
CSCs.
Dr. Yoshiteru Murofushi from the Laboratory 
of Malignancy Control Research, Medical Innovation 
Center at Kyoto University Graduate School of Medicine, 
presented a new disease model of pheochromocytoma 
using VHL patient-derived iPS cells. Von Hippel-Lindau 
(VHL) disease is an autosomal dominant inherited, 
family tumor syndrome caused by a germ line mutation 
in the VHL tumor suppressor gene. The major problem 
of research for VHL disease is the lack of disease model 
that successfully recapitulate human disease phenotypes 
in vitro and in vivo. To establish novel experimental 
model, Dr. Murofushi’s laboratory has used VHL patient-
derived human iPS cells (VHL iPS) to differentiate 
in culture. Although the remaining wild type VHL 
should be disrupted to recapitulate the development of 
pheochromocytomas, VHL iPS cells might be useful for 
establishing new disease model of VHL disease, especially 
for pheochromocytomas.
Dr. Takayuki Kawai from the Division of 
Hepatobiliary, Pancreas and Transplant Surgery, Kyoto 
University Hospital presented data showing that Keratin 
19-positive cells possess cancer stem cell properties in 
human hepatocellular carcinoma. Dr. Kawai’s  work 
demonstrated that FACS-isolated single K19+ cells 
are able to self-renew, proliferate, exhibit resistance to 
5-fluorouracil, express EMT related genes and form 
tumors in xenograft models and many of these activities 
are blocked by transforming growth factor beta receptor 1 
inhibitor. Interestingly, K19+ HCC patients exhibit larger 
tumors and shorter recurrence-free survival.
Cancer Transcriptome 
Dr. Amit Dutt from The Advanced Centre for 
Treatment, Research and Education in Cancer (ACTEC) 
shared emerging data about the status of Notch pathway in 
an Indian cohort of tongue squamous cell carcinoma, a sub 
type of head and neck cancer. The group performed DNA 
copy number and gene expression profiling of NOTCH 
signaling pathway genes comprising of ligands, receptors 
and target genes using quantitative real-time PCR followed 
by immuno-histochemical analysis of activated NOTCH. 
In addition to the tumor suppressor function of the Notch 
pathway, the data presented underlined high copy number 
and overexpression of NOTCH signaling pathway 
components, consistent with an independent TSCC cohort 
from the TCGA study. Dr. Dutt presented data examining 
the influence of NOTCH1 knockdown on the treatment 
of HNSCC cells with gamma secretase inhibitor XXI to 
achieve an effective inhibition of the growth, survival and 
migration of cells derived from patients of Indian origin.
Dr. Wonshik Han from the Seoul National 
University College of Medicine Korea used the targeted 
kinome sequencing on NGS platform to generate a 
comprehensive profiling of the most frequently altered 
genes and mutations in triple-negative breast cancer 
tissues with matched normal tissues or peripheral blood 
samples. 
Dr. Nuno Barbosa-Morais from the Institute of 
Molecular Medicine highlighted the importance of 
alternative splicing (AS) in cancer and the opportunity 
provided by next-generation sequencing to profile AS 
in tumor samples, having shared preliminary results 
of analyses on RNA-Seq data for clear cell renal cell 
carcinomas and matched normal samples from The 
Cancer Genome Atlas project. It was observed that AS 
patterns primarily separate normal from tumor samples. 
Some of the measured normal/tumor isoform “switches” 
are markers of epithelial-mesenchymal transition 
(EMT). Survival analysis revealed several AS events, 
some reassuringly known to be associated with cancer 
progression, as candidate markers for prognosis, both in 
normal and tumor samples. Gene set enrichment analyses 
revealed differential expression of genes associated with 
oncogenic processes, namely EMT, between survival strata 
defined based on candidate AS events. Dr. Barbosa-Morais 
presentations illustrate the potential of AS signatures 
derived from tumor transcriptome in providing etiological 
leads for cancer progression and as a clinical tool.
Dr. Reshmi G from the Rajiv Gandhi Centre 
for Biotechnology, India, presented the utility of 
computational modeling approach to understand the 
impact of viral oncoproteins upon microRNA clusters in 
cancer.  The goal of these integrated in-silico genomic 
studies to identify microRNA and transcription factor-
mediated regulatory networks as early detection or 
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prognostic markers in HPV induced cervical cancer. 
The group systematically explored feed-forward loops 
consisting of miRNAs and transcription factors and 
applied additive and weighted modelling to combine 
possible transcription factor-miRNA target predictions 
to identify the regulation change at a specific gene 
set, pathway, or interacting network. The approach 
successfully identified novel, candidate miRNA-TF 
networks, for further experimental design.
Dr. Raja Mazumdar from the George Washington 
University presented exciting way to conduct pan-cancer 
analyses because cancer mutation and expression data 
is distributed in multiple databases. We have integrated 
cancer related mutation and expression data from multiple 
databases and publications to create two comprehensive 
mutation and expression databases called BioMuta and 
BioExpress. The group then used these databases to 
identify driver mutations present in multiple cancers and 
identified 62 mutations in 13 genes affecting functional 
sites such as DNA and ATP binding and also various 
post-translational modifications (PTM) sites. Key driver 
mutations identified includes p53 acetylation and zinc 
binding sites, CTNNB1 phosphorylation sites and SF3B1 
ubiquitylation site. Initial expression data analysis show 
that genes which are highly mutated in cancer usually 
do not show differential expression in tumors compared 
to adjacent normal tissue. It is hoped that the approach 
undertaken by Dr. Muzumdar’s lab will facilitate 
identification of priority diagnostic and therapeutic targets.
Tumor Heterogeneity
Dr. Seishi Ogawa, Professor of Pathology and 
Tumor Biology at the Graduate School of Medicine Kyoto 
University presented a plenary lecture on mutational 
landscape and clonal architecture in low-grade gliomas. 
Dr. Ogawa shared his experience with the pathogenesis of 
lower grade glioma which if not treated early on leads to 
devastating high grade gliomas.  Despite recent findings 
of frequent mutations in IDH1 and other genes, our 
knowledge about the pathogenesis of lower grade is still 
incomplete.  By combining high-throughput sequencing 
data of 760 cases from two large cohorts with extensive 
validation sequencing, the team delineated the entire 
picture of genetic alterations and affected pathways 
in Lower grade gliomas with sensitive detection of 
novel drivers.  Lower grade gliomas are classified into 
three distinct subtypes characterized by discrete sets 
of mutations and distinct clinical behaviors.  Mutations 
showed significant positive/negative correlations and 
chronological hierarchy as inferred from different 
allelic burdens among coexisting mutations, suggesting 
functional interplays between mutations that drive clonal 
selection.  Based on an extensive serial/multi-regional 
sampling analyses, Dr. Ogawa’s work further revealed 
high degrees of temporal/spatial heterogeneity generated 
during tumor expansion and relapse, which should be 
shaped by complex, but ordered processes of multiple 
clonal selections/evolutions.
Dr. Radhakrishna Pillai from the Rajiv Gandhi 
Center for Biotechnology presented recent findings 
showing that a small fraction of drug-resistant cells, 
named “persister cells,” may contribute to the tumor 
recurrence via contributing to tumor heterogeneity. Using 
experimental models, Dr. Pillai shared data demonstrating 
that persister cells remain quiescence and rarely enter into 
the cell cycle. However, such cells exhibit tumor stem 
cells characteristics and eventually lead to cell population 
with increased heterogeneity with respect to cell growth, 
invasion, response to drugs and tumor initiation potential. 
The team has further subjected diverse cell populations 
to RNA sequencing to understand both the passive and 
driving pathways that might be involved in drug-escape 
and re- emergence. The team used stable cancer cells 
expressing redox sensor and presented data showing that 
the emergence of drug resistant cells was accompanied 
by chronic autophagy followed by Parkin-dependant 
mitophagy and increased heterogeneous cell populations. 
Dr. Pillai suggested that such persister cells are likely to 
counteract the beneficial effects of chemotherapy and 
radiotherapy and present development of approaches to 
prevent emergence of drug-resistance cell populations.
Dr. Rakesh Kumar from GW Washington University 
presented a plenary lecture highlighting the lessons 
from RNA-sequencing of breast cancer sub-types in 
identifying the hub networks and potential new regulatory 
molecules. This approach re-emphasized the notion of 
genomic heterogeneity which, at-least, in-part, might be 
arising from differential splicing and promoter switching 
[3]. These earlier studies allowed the team to recognize 
the limitations of such an approach as most breast 
cancer sub-types are clonal in origin. To experimentally 
address the issue of genomic heterogeneity, Dr. Kumar 
laboratory decided to define the HER2 transcriptome as 
an example by generating isogenic MDA-MB-231 and 
MDA-MB-468  breast cancer cells stably overexpressing 
HER2. To start revealing the nature of HER2-regulated 
genes globelly, the team subjected such isogenic clones 
to microarray and RNA-sequencing approaches. Results 
from the microarray study identified HER2-influenced 
genomic elements shared among two cell lines, some of 
which also overlapped with that of patient microarray 
datasets [4]. In addition, Dr. Kumar presented scientific 
highlights pertaining to global transcriptomic changes and 
differential splicing of HER2-overexpressing isogenic 
clones as revealed by RNA-sequencing – a project 
completed in July 2014 but yet to be summarized in 
a manuscript by Ms. Prakriti Mudvari as a part of her 
dissesration research work with Dr. Kumar [5]. Following 
the leads from mRNA-validation studies by Ms. Mudvari, 
Dr. Kumar also presented preliminary data about the 
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expression of two newly identified HER2-regulated 
proteins: ABCC3 with an established role in therapeutic 
resistance and a splicing factor with role in transformation. 
Interestingly, HER2-regulated ABCC3 protein with a 
putative role in therapeutic resistance was found to exist 
as multiple isoforms, raising the possibility of protein 
isoform-specific functions in therapeutic resistance. 
Further,  these newly identified HER2-regulated molecules 
are highly overexpressed as well as co-overexpressed with 
HER2 in breast cancer and cancer, at-large, in genomic 
databases. Dr. Kumar’s also discussed another HER2-
centered collaborative study involving HER2 ChIP-
sequencing to determine the genomic effects of the nuclear 
HER2 in stimulated breast cancer cells and how this will 
help to broaden the HER2 transcriptome. He closed his 
presentation with a working model to understand the 
molecular basis of co-overexpression and upregulation 
of these newly recognized HER2-target proteins with 
functions in drug-sensitivity and transformation, and 
perhaps, in HER2-biology at-large.
Tumor Biology 
Dr. Makoto Noda from the Laboratory for 
Malignancy Control Research at Kyoto University 
Graduate School of Medicine presented a plenary lecture 
on RECK: a tumor suppressor downregulated by multiple 
oncogenic pathways. Dr. Noda discussed the biology of 
RECK tumor suppressor which encodes a membrane-
anchored glycoprotein with an ability to regulate matrix 
metalloproteinases. Accordingly, viable Reck–deficient 
mice was found to be prone to spontaneous tumorigenesis 
while forced RECK expression leads to inhibition of 
angiogenesis, invasion, and metastasis in model systems. 
Clinically, RECK downregulation in cancer correlates 
well with a poor prognosis.  Dr. Noda believes that RECK 
provides a unique opportunity to reactivate the dormant 
RECK in cancer cells with a goal to suppress malignant 
phenotypes.
Dr. Luis Costa from the Institute of Molecular 
Medicine and Medical Faculty of Lisbon University 
highlighted the significance of molecular understanding 
of distinct biologic steps until the formation of clinical 
detectable metastases in selecting cancer patients at 
higher risk for metastases, and also debated if bone 
metastasis is a useful paradigm to follow for developing 
effective therapeutics. Dr. Costa presented data showing 
overexpression of Bone Metastases (BM) genes in tumor 
cells residing in BMs - independent of primary tumor 
type - and provided support to the cooperative function 
among IL11/CTGF, IL11/ADAMTS1, CTGF/CXCR4, 
CTGF/ADAMTS1, and MMP-1/ADAMTS1, in the bone 
microenvironment [6]. Dr. Costa’s team shared data about 
the correlation between the amplification and expression 
of Metadherin (MTDH) which contains a lung vasculature-
binding domain, and lung metastases of colorectal cancer 
[7]. For the first time, Dr. Costa’s work showed that high 
MTDH expression is an independent factor for lung-
relapse and survival and could be a potential biomarker 
for lung relapse in colon cancer. Finally, Prof. Costa 
stressed the need to expend the lessons of organ-specific 
colonization from bone metastases to other common sites 
of metastases, and provided a peek into very interesting 
set of experiments in his laboratory wherein the team 
is undertaking steps to capture the dynamic of gene 
expression during consecutive episodes of metastases in 
the same patient. 
Dr. Dominique Scherer from the German Cancer 
Research Center, Heidelberg shared her vision of 
pharmacogenetics in colorectal cancer prevention using 
non-steroidal anti-inflammatory drugs (NSAIDs) which 
inhibit prostaglandin synthesis by targeting COX-
enzymes. Although recent meta-analyses showed the effect 
of NSAIDs on primary cancer prevention, metastasis 
prevention and patient survival, the risk of gastrointestinal 
toxicity among NSAID remains high.  Dr. Scherer 
presented data showing that genetic variation in specific 
alleles in distinct genes including PTGS1, PTGS2, PGDH 
and UGT modifies the beneficial effects of NSAIDs in 
colorectal cancer and may be also important in colorectal 
cancer predisposition. Her data showed that genetic 
variants in PGES, CRP, SRC and GPX3 were associated 
with increased risk of cardiac symptoms/toxicity among 
NSAID users. Therefore, it is crucial to identify genetic 
variants that interact with NSAIDs in colorectal cancer 
prevention and drug-related toxicities to establish targeted 
chemoprevention strategies.
Dr. Norman Lee from the George Washington 
University presented data about potential molecular basis 
of population disparities of prostate cancer risk with a 
particular focus on differential methylation patterns, 
expression of splicing factor and variants. The team 
found population-based differential alternative splicing 
of several key oncogenes in specimens from of African 
American (AA) with non-AA patients and generated 
variants tend to exert a strong oncogenic phenotype. 
Further, this phenomenon correlated well with race 
associated methylation patterns and expression of splicing 
factors. Prof. Lee hypothesize that certain splice variants 
specific to AA population encode gene products with a 
stronger oncogenic activity and thus, could explain, in-
part, the noted risk of prostate cancer in certain population. 
Breast Cancer Genomics 
Dr. Hisataka Sabe from the Department of 
Molecular Biology, Hokkaido University Graduate School 
of Medicine discussed the significance of mesenchymal 
machinery in metastasis in different cancer sub-types with 
a particular focus on the small GTPase Arf6 signaling 
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pathway. Dr. Sabe presented data showing that Arf6 
interacts with AMAP1 which in-turn, binds to EPB41L5 
– a component of mesenchyme – and hence, contributes 
to mesenchymal properties that might be cancer-type 
specific. Because AMAP1-EPB41L5 interactions regulate 
E-cadherin and β1 integrin signaling, Arf6 is believed 
to play a mechanistic role in epithelial-mesenchymal 
transition. Dr. Sabe also presented data showing the 
activation of Arf6 by two distinct mechanisms – by the 
cell surface tyrosine kinases in breast cancer and by 
G-protein coupled receptors (GPCRs) in clear cell renal 
cell carcinomas. Therefore, Arf6 activation - independent 
of its upstream mode of stimulation- cooperates with the 
Arf6-AMAP1-EPB41L5 pathway to promote EMT. Dr. 
Sabe closed his presentation by highlighting the roles 
of genome in eliciting the Arf6-driven EMT pathway in 
metastasis of human cancer. 
Dr. Sudeep Gupta from the Tata Medical Center 
discussed a recently conducted randomized study wherein 
a single depot injection of progesterone prior to surgery in 
patients with node positive breast cancer exhibited clinical 
benefits [8]. Dr. Gupta shared results from on-going studies 
designed to understand the potential mechanisms behind 
the noted effects of progesterone. Using cell-based model 
systems, the team performed genome wide expression 
analysis and identified serum and glucocorticoid regulated 
kinase SGK1 as a progesterone up-regulated transcript. 
In addition, progesterone also down regulated two 
microRNAs that target the 3’UTR region of SGK1. Dr. 
Gupta proposed a novel dual-regulatory model wherein 
progesterone up-regulates SGK1 as well as down-
regulates the expression of microRNAs which in-turn, 
targets SGK1. He also suggested that progesterone could 
downregulate the expression of its own receptor through 
upregulation of a microRNA. 
Dr. Louis Chow from Organisation for Oncology 
and Translational Research and UNIMED Medical 
Institute presented a comprehensive comparative summary 
of available diagnostic gene signatures and assays for 
breast cancer prognostic and/or predictive assessment. 
Dr. Chow highlighted the benefits of including the 
proliferation or estrogen receptor (ER) pathway in 
assay platforms for prognosis. For example, the 21-gene 
Oncotype DX assay is a prognostic and predictive test 
that uses ER, proliferation, HER2 genes, amongst others 
to normalize for RNA quantity, and the expression levels 
are used to calculate a recurrence score for ER positive, 
node negative breast cancer. In contrast, Endopredict uses 
12-genes not involving ER, PR or HER2 status to classify 
the prognosis of HER2 negative breast cancer. The gene 
signatures also predict the risk of recurrence for patients 
- high probability of metastasis, free survival, or high risk 
for distant metastasis.
Targeted Cancer Therapeutics
Dr. Stefan Knapp from the University of Oxford 
presented an update on recent development of chemical 
probes for epigenetic reader domains of the bromodomain 
family. Bromodomains (BRDs) are evolutionary 
conserved protein interaction modules that specifically 
recognize ε-N-lysine acetylation motifs, a key event in the 
reading process of epigenetic marks. The human proteome 
encodes 61 of these highly diverse domains present 
in 41 mainly nuclear proteins. Recently, Dr. Knapp’s 
research group has developed a platform for screening 
and designing of specific bromodomain inhibitors based 
on a large number of crystal structures and biochemical/
cell based assays [9]. The probe project at the SGC 
(www.sgc.ox.ac.uk) resulted in the development of a 
comprehensive set of chemical probes covering most the 
human bromodomain family. The development of these 
research tools led to new validation of new targets and 
the initiation of first set of clinical studies in cancer [10, 
11]. As an example of the translational aspects of this 
effort, Dr. Knapp reported on the development of dual 
kinase/bromodomain inhibitors [12] and specific chemical 
probes targeting the bromodomains of CBP/P300 [13] and 
BRPF1B [unpublished]. 
Dr. Junko Murai from the Medical Innovation 
Center at the Kyoto University Graduate School of 
Medicine presented new research revealing a novel 
mechanism of action for poly(ADP-ribose) polymerase 
(PARP) inhibitors – the most promising anti-cancer 
agents. The mechanism of anticancer effect of PARP 
inhibitors has been interpreted by single strand break 
(SSB) repair inhibition through catalytic PARP inhibition. 
Her team discovered that inhibitors promote trapping of 
PARPs at the damaged DNA site and that trapped PARP-
DNA complexes are more cytotoxic than unrepaired 
single-stranded breaks [14]. Dr. Murai also found that the 
potency of PARP-trapping is markedly (more than 1,000 
folds) different among five clinical PARP inhibitors in-
spite of an equivalent high catalytic PARP inhibition [15]. 
Dr. Murai stressed the need to start considering the PARP-
trapping efficacy as an addition variable for clinical utility 
of a given PARP inhibitor. 
Personalized Medicine
Dr. Stephen Fox from Peter MacCallum Cancer 
Centre in Melbourne shared his vision of “Cancer 2015 
- a model for personalized medicine” program. Cancer 
2015 study is a large-scale, prospective, multi-site 
cohort of newly diagnosed cancer patients from Victoria, 
Australia with 1718 patients recruited, 854 patients of 
which have been currently sequenced for 48 cancer genes. 
Clinically relevant mutations were identified in 63% 
Genes & Cancer7www.impactjournals.com/Genes&Cancer
of patients, with 26% of patients displaying a mutation 
with therapeutic implications. While the prevalence 
of mutations was consistent with other institutionally 
based series for some tumor types (breast carcinoma 
and colorectal adenocarcinoma), others were different 
(lung adenocarcinoma and head and neck squamous cell 
carcinoma) which has significant implications for health 
economic modelling of particular targeted agents. Further, 
in some tumour types new areas of research were identified 
through recognition of novel genotypes. Reliable delivery 
of a diagnostic assay to screen for a range of actionable 
mutations was achieved, providing evidence for a re-
classification of some cancers and opening unexpected 
avenues for investigation and treatment of cancer patients. 
Dr. Fox also presented his vision about the planned 
utilization of the Cancer 2015 study for modeling health 
economics of particular targeted agents.
Dr. Fumihiko Matsuda from the Center for Genomic 
Medicine at Kyoto University Graduate School of 
Medicine presented the utility of a large-scale genome for 
comprehensive human biology. As a model of “Human 
Biology”, the team initiated “The Nagahama Cohort 
Study” - a community-based prospective genome cohort 
study in Nagahama City. The baseline survey started in 
2007, and the enrollment of 10,082 healthy residents 
was completed in 2010. In addition to the collection of 
health-related information and the measurement of 115 
biochemical and hematological traits, the team conducted 
an integrated comics study. A genome scan using SNP 
arrays was initiated in 2009, and approximately 4,000 
DNA samples have been analyzed to date.  Dr. Matsuda 
presented interim analysis of overall data and discuss the 
results of the cross-sectional analysis.
CONCLUSIONS
The symposium achieved one of the core GCGC 
goals to bring together its founding members from 
six institutions as well as a large number of interested 
scientists and potential collaborators to share their exciting 
research findings. Looking at the trend during the past 
meetings, it was obvious that certain research themes such 
as tumor heterogeneity and transcriptome have evolved 
over the years. It remains unclear whether we are able to 
harvest the fruits of whole genome sequencing completed 
so far. In general, each session provided a spectrum of 
findings ranging from an overview to specific research 
questions that might be acting as a bottleneck to move 
the field forward. As always the case in science and 
medicine, many of the presentations raised more exciting 
questions for investigation while addressing a well-defined 
research problem. The organizing committee as well as 
some of meeting participants observed the need to include 
additional shared activities some of which might require 
financial resources. The group identified a short list of 
broad activities that might be feasible within the current 
framework of consortium members and the precise nature 
of such collaborative theme is likely to be evolved soon. 
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